This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horn, J. Articles by Limburg, M. Search for Related Content PubMed PubMed Citation Articles by Horn, J. Articles by Limburg, M. Pubmed/NCBI databases Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Acute Stroke Syndromes Emergency treatment of Stroke Neuroprotectors

(Stroke. 2001;32:570.)
© 2001 American Heart Association, Inc.

Comments, Opinions, and Reviews

Calcium Antagonists for Ischemic Stroke

A Systematic Review

J. Horn, MD M. Limburg, MD, PhD

From the Departments of Neurology (J.H., M.L.) and Medical Informatics (M.L.), Academic Medical Center, University of Amsterdam (Netherlands).

Correspondence to J. Horn, AMC J-254, PO Box 22700, 1100 DE, Amsterdam, Netherlands. E-mail jhorn{at}wxs.nl

Background and Purpose—Stroke is a common disease, and many trials with calcium antagonists as possible neuroprotective agents have been conducted. The aim of this review is to determine whether calcium antagonists reduce the risk of death or dependency after acute ischemic stroke.

Methods—Acute stroke trials were identified with help of the Cochrane Collaboration Stroke Group and personal contacts. All randomized trials (published and unpublished) investigating a calcium antagonist (acting on voltage-sensitive calcium channels) were included. Poor outcome, defined as death or dependency in activities of daily living, was used as main outcome. Analyses were, if possible, "intention-to-treat"; pooled relative risks with 95% CIs were calculated.

Results—Forty-seven trials were identified, of which 29 were included (7665 patients). No effect of calcium antagonists on poor outcome at the end of follow-up (relative risk, 1.04; 95% CI, 0.98 to 1.09) or on death at end of follow-up (relative risk, 1.07; 95% CI, 0.98 to 1.17) was found. Sensitivity analyses on route of administration and time interval between stroke and start of treatment showed no effect on outcome. In subgroups of unpublished and methodologically sound trials, a statistically significant negative effect for calcium antagonists was found. This contrasts with results of published trials and trials of moderate or poor methodological quality.

Conclusions—The presented evidence rules out a clinically important effect of calcium antagonists after ischemic stroke. The large amount of data leads to narrow CIs with no significant heterogeneity, and the overall results are therefore likely to be statistically robust.

Key Words: calcium channel blockers • cerebrovascular disorders • meta-analysis

This article has been cited by other articles:

				L. S. Deshpande, D. D. Limbrick Jr., S. Sombati, and R. J. DeLorenzo Activation of a Novel Injury-Induced Calcium-Permeable Channel That Plays a Key Role in Causing Extended Neuronal Depolarization and Initiating Neuronal Death in Excitotoxic Neuronal Injury J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 443 - 452. [Abstract] [Full Text] [PDF]

				P. K Shukla, V. K Khanna, M M. Ali, R. Maurya, M Y Khan, and R. C Srimal Neuroprotective effect of Acorus calamus against middle cerebral artery occlusion-induced ischaemia in rat Human and Experimental Toxicology, April 1, 2006; 25(4): 187 - 194. [Abstract] [PDF]

				A. J. Williams, F. C. Tortella, X. M. Lu, J. E. Moreton, and J. A. Hartings Antiepileptic Drug Treatment of Nonconvulsive Seizures Induced by Experimental Focal Brain Ischemia J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 220 - 227. [Abstract] [Full Text] [PDF]

				C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome Stroke, May 1, 2004; 35(5): 1216 - 1224. [Abstract] [Full Text] [PDF]

				P. Pound, S. Ebrahim, P. Sandercock, M. B Bracken, and I. Roberts Where is the evidence that animal research benefits humans? BMJ, February 28, 2004; 328(7438): 514 - 517. [Full Text] [PDF]

				G. H. Danton and W. D. Dietrich The Search for Neuroprotective Strategies in Stroke AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 181 - 194. [Full Text] [PDF]

				M. van der Flier, S. P. M. Geelen, J. L. L. Kimpen, I. M. Hoepelman, and E. I. Tuomanen Reprogramming the Host Response in Bacterial Meningitis: How Best To Improve Outcome? Clin. Microbiol. Rev., July 1, 2003; 16(3): 415 - 429. [Abstract] [Full Text] [PDF]

				A. Davalos, J. Castillo, J. Alvarez-Sabin, J. J. Secades, J. Mercadal, S. Lopez, E. Cobo, S. Warach, D. Sherman, W. M. Clark, et al. Oral Citicoline in Acute Ischemic Stroke: An Individual Patient Data Pooling Analysis of Clinical Trials Stroke, December 1, 2002; 33(12): 2850 - 2857. [Abstract] [Full Text] [PDF]

				R. C. Brown and T. P. Davis Calcium Modulation of Adherens and Tight Junction Function: A Potential Mechanism for Blood-Brain Barrier Disruption After Stroke Stroke, June 1, 2002; 33(6): 1706 - 1711. [Abstract] [Full Text] [PDF]

				M. Spedding Letters to the Editor: Reasons Why Stroke Trials Underestimate the Neuroprotective Effects of Drugs Stroke, January 1, 2002; 33(1): 324 - 325. [Full Text] [PDF]